Most Favored Nation (MFN) Model
Conducted rapid analysis of Medicare rulemaking on the Most Favored Nation model introduced by CMMI. Assessed methodology, drugs impacted, and provider perspective. Modeled drug-specific impact per administration and annually over the model’s 4 year transition period using ADVI Strategic Analytics and Value Economics (SAVE), and modeled the specialty-level impact for providers based on historical billing. Developed and led market access and field reimbursement training, including key messages and FAQs for field teams.